Aging, Dementia, Cognitive, and Behavioral Neurology
Gil Rabinovici MD
Frontotemporal dementia (FTD) and chronic traumatic encephalopathy (CTE) represent important, likely underdiagnosed, causes of neurodegenerative dementia. FTD is as common as Alzheimer's disease (AD) in patients presenting with an early-onset dementia (under age 65), whereas CTE is increasingly recognized through autopsy in individuals exposed to repetitive mild traumatic brain injury (through contact sports, military exposures, and other high-risk endeavors) who present with neurobehavioral decline. Faculty will present a case-based approach to introduce the diverse clinical presentations of these disorders, and provide an update on biomarker development and advances in understanding the genetic and molecular underpinnings of these disorders.
This program complements C51: Non-Alzheimer's Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias, but covers independent topics.
Participants should be able to apply up-to-date clinical criteria and diagnostic tools to classify the different subtypes of FTD, to identify individuals at risk for CTE, and to differentiate FTD and CTE from AD. Improving clinical diagnosis and in vivo prediction of molecular pathology is critical in preparation for emerging disease-specific therapies for these disorders.
Medical Knowledge, Patient Care
Program Speakers - Tentative
1:00 PM - 1:45 PM
Frontotemporal Dementia and Primary Progressive Aphasia
Gil Dan Rabinovici MD
1:45 PM - 2:00 PM
Questions and Answers
2:00 PM - 2:45 PM
Chronic Traumatic Encephalopathy
Andrew E. Budson MD
2:45 PM - 3:00 PM
Questions and Answers
Andrew E. Budson, MD
Dr. Budson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lilly and Axovant.
Gil Dan Rabinovici, MD
Dr. Rabinovici has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech and Merck. Dr. Rabinovici has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Rabinovici has received research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Piramal.